About RayzeBio
RayzeBio is a company based in San Diego (United States) founded in 2019 by Deborah Charych and Aaron Kantoff was acquired by Bristol-Myers Squibb in December 2023.. RayzeBio has raised $426.43 million across 4 funding rounds from investors including ARE, RayzeBio and Orbimed. RayzeBio offers products and services including RYZ101, GEP-NETs Program, and ES-SCLC Program. RayzeBio operates in a competitive market with competitors including Merck, Roivant Sciences, Gilead, Lilly and Vertex Pharmaceuticals, among others.
- Headquarter San Diego, United States
- Founders Deborah Charych, Aaron Kantoff
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$426.43 M (USD)
in 4 rounds
-
Latest Funding Round
$167.9 M (USD), Series D
Aug 25, 2022
-
Investors
ARE
& 23 more
-
Employee Count
Employee Count
-
Acquired by
Bristol-Myers Squibb
(Dec 26, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of RayzeBio
RayzeBio offers a comprehensive portfolio of products and services, including RYZ101, GEP-NETs Program, and ES-SCLC Program. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Targets neuroendocrine tumors through targeted radioisotope therapy.
Develops therapies for gastroenteropancreatic neuroendocrine tumors.
Focuses on extensive-stage small cell lung cancer treatments.
Unlock access to complete
Unlock access to complete
Funding Insights of RayzeBio
RayzeBio has successfully raised a total of $426.43M across 4 strategic funding rounds. The most recent funding activity was a Series D round of $167.9 million completed in August 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series D — $167.9M
-
First Round
First Round
(05 Aug 2020)
- Investors Count 23
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2022 | Amount | Series D - RayzeBio | Valuation | Viking Global Investors , Sofinnova Investments | |
| Jun, 2021 | Amount | Series C - RayzeBio | Valuation | Venrock | |
| Nov, 2020 | Amount | Series B - RayzeBio | Valuation | Venrock |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in RayzeBio
RayzeBio has secured backing from 24 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, RayzeBio and Orbimed. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private investment firm focused on multiple sectors
|
Founded Year | Domain | Location | |
|
Biotech funding, drug development support, and investment in life sciences.
|
Founded Year | Domain | Location | |
|
Private equity and hedge fund investments in healthcare are managed.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by RayzeBio
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - RayzeBio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Rayzebio Comparisons
Competitors of RayzeBio
RayzeBio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck, Roivant Sciences, Gilead, Lilly and Vertex Pharmaceuticals, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Pharmaceutical products are manufactured and marketed worldwide.
|
|
| domain | founded_year | HQ Location |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others
|
|
| domain | founded_year | HQ Location |
Traditional pharmaceutical medicines are developed for multiple health fields.
|
|
| domain | founded_year | HQ Location |
Developer of drugs for the treatment of multiple disorders
|
|
| domain | founded_year | HQ Location |
Biopharmaceutical research and drug development are conducted globally by AbbVie.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Rayzebio
Frequently Asked Questions about RayzeBio
When was RayzeBio founded?
RayzeBio was founded in 2019 and raised its 1st funding round 1 year after it was founded.
Where is RayzeBio located?
RayzeBio is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Who is the current CEO of RayzeBio?
Ken Song is the current CEO of RayzeBio.
Is RayzeBio a funded company?
RayzeBio is a funded company, having raised a total of $426.43M across 4 funding rounds to date. The company's 1st funding round was a Series B of $105M, raised on Aug 05, 2020.
What does RayzeBio do?
RayzeBio was founded in 2019 and is headquartered in San Diego, United States. Operations are centered on research and development within the biotechnology sector, with a focus on manufacturing targeted cancer drugs. Leadership includes co-founders Deborah Charych as Chief Technology Officer and Aaron Kantoff, alongside CEO Ken Song. The companys activities emphasize innovative therapies for oncology applications.
Who are the top competitors of RayzeBio?
RayzeBio's top competitors include Merck, Roivant Sciences and AbbVie.
What products or services does RayzeBio offer?
RayzeBio offers RYZ101, GEP-NETs Program, and ES-SCLC Program.
Who are RayzeBio's investors?
RayzeBio has 24 investors. Key investors include ARE, RayzeBio, Orbimed, Bristol-Myers Squibb, and Perceptive Advisors.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.